Antivascular endothelial growth factors in age-related macular degeneration

Developments in Ophthalmology

Volumn 46, Issue , 2010, Pages 21-38

  Schmidt Erfurth, Ursula ^a   Pollreisz, Andreas ^a   Mitsch, Christoph ^a   Bolz, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; APTAMER; BEVACIZUMAB; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A;

ARTICLE; DRUG ANTAGONISM; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84925969665     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000320007     Document Type: Article

References (99)

1. VanNewkirk MR, Nanjan MB, Wang JJ, et al: The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000;107:1593-1600.
2. Mitchell P, Smith W, Attebo K, Wang JJ: Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-1460.
3. Buch H, Nielsen N V, Vinding T, et al: Fourteen-year incidence, progression, and visual morbidity of agerelated maculopathy: the Copenhagen City Eye Study. Ophthalmology 2005;112:787-798.
4. Klein R, Klein BE, Knudtson MD, et al: Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007;114:253-262.
5. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
6. Reynolds R, Hartnett ME, Atkinson JP, et al: Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009;50:5818-5827.
7. Morohoshi K, Goodwin AM, Ohbayashi M, Ono SJ: Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J Autoimmun 2009;33:247-254.
8. Okemefuna AI, Nan R, Miller A, et al: Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem 2010;285:1053-1065.
9. Schmidt-Erfurth U, Pruente C: Management of neovascular age-related macular degeneration. Prog Retin Eye Res 2007;26:437-451.
10. Schmidt-Erfurth U, Richard G, Augustin A, et al: Guidance for the treatment of neovascular agerelated macular degeneration. Acta Ophthalmol Scand 2007;85:486-494.
11. Ferrara N, Gerber H P, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
12. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
13. Ishibashi T, Hata Y, Yoshikawa H, et al: Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-167.
14. Kvanta A: Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006;84:282-288.
15. Petrova T V, Makinen T, Alitalo K: Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999;253:117-130.
16. Frank RN, Amin RH, Eliott D, et al: Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393-403.
17. Kvanta A, Algvere PV, Berglin L, Seregard S: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934.
18. Kliffen M, Sharma HS, Mooy CM, et al: Increased expression of angiogenic growth factors in agerelated maculopathy. Br J Ophthalmol 1997;81:154-162.
19. Shima DT, Adamis AP, Ferrara N, et al: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor as the mitogen. Mol Med 1995;1:182-193.
20. Funk M, Karl D, Georgopoulos M, et al: Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399.
21. Waheed NK, Miller JW: Aptamers, intramers, and vascular endothelial growth factor. Int Ophthalmol Clin 2004;44:11-22.
22. Famulok M, Mayer G, Blind M: Nucleic acid aptamers - from selection in vitro to applications in vivo. Acc Chem Res 2000;33:591-599.
23. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-822.
24. Schachat AP: New treatments for age-related macular degeneration. Ophthalmology 2005;112:531-532.
25. Ruckman J, Green LS, Beeson J, et al: 2'-Fluoropyrimidine RNA-based aptamers to the 165-aminoacid form of vascular endothelial growth factor (VEGF-165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7 encoded domain. J Biol Chem 1998;273:20556-20567.
26. Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-152.
27. Eyetech Study Group: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-986.
28. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
29. Spaide R: New treatments for AMD. Ophthalmology 2006;113:160-161.
30. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
31. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
32. Adding a humanized antibody to vascular endothelial growth factor (bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 2003;3:85-88.
33. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
34. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
35. ab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-544.
36. Heiduschka P, Fietz H, Hofmeister S, et al: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823.
37. Shahar J, Avery RL, Heilweil G, et al: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
38. Michels S, Rosenfeld PJ, Puliafito CA, et al: Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration 12-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
39. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: 24-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002.e1-12.
40. Geitzenauer W, Michels S, Prager F, et al: Comparison of 2.5 and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: 24-week results of an uncontrolled, prospective cohort study. Retina 2008;28:1375-1386.
41. Bolz M, Michels S, Geitzenauer W, et al: Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 2007;91:785-789.
42. Rosenfeld PJ, Fung AE, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
43. Weigert G, Michels S, Sacu S, et al: Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-360.
44. Hahn R, Sacu S, Michels S, et al: Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration (in German). Ophthalmologe 2007;104:588-593.
45. Costa RA, Jorge R, Calucci D, et al: Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 doseescalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
46. Kiss C, Michels S, Prager F, et al: Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-881.
47. ̊) in neovascular agerelated macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol 2009: [Epub ahead of print].
48. Sacu S, Michels S, Prager F, et al: Randomised clinical trial of intravitreal Avastin vs. photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 2009;23:2223-2227.
49. Spaide R F, Laud K, Fine H F, et al: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
50. Rich RM, Rosenfeld PJ, Puliafito CA, et al: Shortterm safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
51. Avery RL, Pieramici DJ, Rabena MD, et al: Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006;113:363-372.e5.
52. Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
53. Artunay O, Yuzbasioglu E, Rasier R, et al: Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:2187-2193.
54. Sato T, Emi K, Ikeda T, et al: Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010;117:512-516.e1-2.
55. Yenerel NM, Dinc UA, Gorgun E: A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24:362-363.
56. Yamashiro K, Tsujikawa A, Miyamoto K, et al: Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010;30:485-490.
57. Georgopoulos M, Polak K, Prager F, et al: Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-462.
58. Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
59. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432-1444.
60. TAP Report 1: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials. Arch Ophthalmol 1999;117:1329-1345.
61. TAP Report 2: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials. Arch Ophthalmol 2001;119:198-207.
62. Andrew NA, Lisa T, Carol YC, Angele S: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-874.e3.
63. Mitchell P, Korobelnik J F, Lanzetta P, et al: Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2009;20:20.
64. Holz FG, Korobelnik J F, Lanzetta P, et al: The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2009;51:405-412.
65. Schmidt-Erfurth U, Eldem B, Guymer R, et al.; on behalf of the EXCITE Study Group: Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration. Ophthalmology 2010 (in press).
66. Schmidt-Erfurth U: Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010;9:149-165.
67. Carl DR, David MB, Prema A, et al: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.e5.
68. Lalwani GA, Rosenfeld PJ, Fung AE, et al: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1.
69. Quan Dong N, Syed Mahmood S, Gulnar H, et al: A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522.e1-14.
70. Do DV: Antiangiogenic approaches to age-related macular degeneration in the future. Ophthalmology 2009;116(suppl 1):S24-S6.
71. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epitheliumderived factor. Invest Ophthalmol Vis Sci 2003;44:4473-4480.
72. Kiss CG, Simader C, Michels S, Schmidt-Erfurth U: Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study. Br J Ophthalmol 2008;92:1620-1627.
73. Schmidt-Erfurth U, Wolf S: Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008;92:1628-1635.
74. Srinivasan VJ, Wojtkowski M, Witkin AJ, et al: High-definition and three-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:2054.e1-14.
75. Golbaz I, Ahlers C, Goesseringer N, et al: Automatic and manual segmentation of healthy retinas using high-definition optical coherence tomography. Acta Ophthalmol 2009: [Epub ahead of print].
76. Mylonas G, Ahlers C, Malamos P, et al: Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol 2009;93:1453-1460.
77. Gotzinger E, Pircher M, Baumann B, et al: Threedimensional polarization sensitive OCT imaging and interactive display of the human retina. Opt Express 2009;17:4151-4165.
78. Ahlers C, Schmidt-Erfurth U: Three-dimensional high resolution OCT imaging of macular pathology. Opt Express 2009;17:4037-4045.
79. Ahlers C, Gotzinger E, Pircher M, et al: Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51:2149-2157.
80. Puliafito CA, Hee MR, Lin C P, et al: Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217-229.
81. Pieroni CG, Witkin AJ, Ko TH, et al: Ultrahigh resolution optical coherence tomography in non-exudative age-related macular degeneration. Br J Ophthalmol 2006;90:191-197.
82. Malamos P, Sacu S, Georgopoulos M, et al: Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci 2009;50:4926-4933.
83. Golbaz I, Ahlers C, Schutze C, et al: Influence of antiangiogenetic therapy on retinal thickness values in age-related macular degeneration (in German). Ophthalmologe 2009;106:1103-1110.
84. Einwallner E, Ahlers C, Golbaz I, et al: Neovascular age-related macular degeneration under anti-angiogenic therapy: subretinal fluid is a relevant prognostic parameter (in German). Ophthalmologe 2010;107:158-164.
85. Andreoli CM, Miller JW: Antivascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-508.
86. Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637.
87. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432-1444.
88. Kaiser PK, Blodi BA, Shapiro H, Acharya NR: Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-1875.
89. Regillo CD, Brown DM, Abraham P, et al: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
90. Shah AR, Del Priore LV: Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 2009;93:1027-1032.
91. Witkin AJ, Vuong LN, Srinivasan VJ, et al: Highspeed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmology 2009;116:956-963.
92. Framme C, Panagakis G, Birngruber R: Effects on choroidal neovascularization after anti-VEGF upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51:1671-1676.
93. Bolz M, Simader C, Ritter M, et al: Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:185-189.
94. Ahlers C, Golbaz I, Stock G, et al: Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 2008;115:e39-e46.
95. Kiss CG, Geitzenauer W, Simader C, et al: Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376-2383.
96. Bakri SJ, Kitzmann AS: Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 2007;143:505-507.
97. Kiss C, Michels S, Prager F, et al: Retinal pigment epithelium tears following intravitreal ranibizumab therapy. Acta Ophthalmol Scand 2007;85:902-903.
98. Chan C K M, Meyer C H M, et al: Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007;27:541-551.
99. Apte RS: Retinal pigment epithelial tear after intravitreal ranibizumab for subfoveal CNV secondary to AMD. Int Ophthalmol 2007;27:59-61.